The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit
The article by Wouters and colleagues
The incremental cost (C) and the incremental effectiveness (E) are the two main parameters of pharmacoeconomics and cost-effectiveness analysis, along with the willingness-to-pay threshold (). The decision rule (eg, in the case of a favourable pharmacoeconomic result) is (C/E) < (equation 1), if based on the ICER, or (Ex–C) > 0 (equation 2), if based on the NMB. Likewise, an unfavourable pharmacoeconomic result is when (C/E) > or when...
Publisher URL: http://heart.bmj.com/cgi/content/short/103/21/1746
DOI: 10.1136/heartjnl-2017-311816
Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.
Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.